News and Announcements
Strong interim results of CAVATAK in Phase 2 Trial
- Published July 19, 2013 10:42AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19 July 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) today announced strong interim results from its Phase 2 clinical trial of CAVATAK™ treatment in late stage melanoma patients.
The interim data shows solid progress towards achieving the primary endpoint of the study and stregthens the evidence of the tolerability of CAVATAK™ in late stage melanoma patients.
Earlier today, Dr Robert Andtbacka, the lead study investigator from the Huntsman Cancer Institute in the USA, presented on the safety and investigator assessed efficacy data from the first 35 patients in the CALM study at the 8th World Congress of Melanoma, Hamburg, Germany.
To read the full ASX announcement, please download the document below.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
